Lyell Immunopharma, Inc.
General ticker "LYEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $155.9M (TTM average)
Lyell Immunopharma, Inc. follows the US Stock Market performance with the rate: 45.1%.
Estimated limits based on current volatility of 6.1%: low 28.85$, high 32.57$
Factors to consider:
- Total employees count: 300 (+33.9%) as of 2024
- Top business risk factors: Insufficient funding, Labor/talent shortage/retention, Market volatility, Product commercialization failure, Market competition
- Current price 20.9% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.43$, 27.63$]
- 2025-12-31 to 2026-12-31 estimated range: [6.92$, 22.07$]
Financial Metrics affecting the LYEL estimates:
- Negative: with PPE of -9.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.96 <= 0.33
- Positive: Investing cash flow per share per price, % of 3.74 > -0.66
- Positive: Shareholder equity ratio, % of 77.99 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term LYEL quotes
Long-term LYEL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $84.68MM | $0.13MM | $0.06MM |
| Operating Expenses | $271.74MM | $247.14MM | $358.82MM |
| Operating Income | $-187.06MM | $-247.01MM | $-358.75MM |
| Non-Operating Income | $3.94MM | $12.38MM | $15.76MM |
| R&D Expense | $159.19MM | $182.94MM | $171.60MM |
| Income(Loss) | $-183.12MM | $-234.63MM | $-342.99MM |
| Profit(Loss)* | $-183.12MM | $-234.63MM | $-342.99MM |
| Stockholders Equity | $833.25MM | $654.95MM | $382.82MM |
| Assets | $937.56MM | $750.03MM | $490.86MM |
| Operating Cash Flow | $-169.56MM | $-163.69MM | $-162.39MM |
| Capital expenditure | $24.28MM | $2.69MM | $0.46MM |
| Investing Cash Flow | $-11.54MM | $184.05MM | $122.42MM |
| Financing Cash Flow | $10.63MM | $1.74MM | $1.33MM |
| Earnings Per Share** | $-0.74 | $-0.93 | $-1.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.